|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the HIV and AIDS Malignancy Branch, the
Dermatology Branch, and the Medicine Branch, National Cancer Institute,
National Institutes of Health, Bethesda, MD.
There is substantial evidence that Kaposi sarcoma-associated
herpesvirus (KSHV) plays an important role in the pathogenesis of all
forms of Kaposi sarcoma (KS). It has been noted that KS commonly occurs
in locations, such as the feet, where tissue may be poorly oxygenated.
On the basis of this observation, the potential role of hypoxia in the
reactivation of KSHV replication was explored by studying 2 KSHV-infected primary effusion lymphoma B-cell lines (BC-3 and BCBL-1)
latently infected with KSHV. Acute and chronic exposure of these cells
to hypoxia (1% O2) induced KSHV lytic replication, as
indicated by an increase in intracellular lytic protein expression and
detection of virus in cell supernatants by Western immunoblotting. In
addition, hypoxia increased the levels of secreted viral
interleukin-6. Moreover, hypoxia enhanced the lytic replication
initiated by the viral inducer 12-O-tetradecanoylphorbol-13-acetate. Desferoxamine and cobalt chloride, 2 compounds that increase the intracellular levels of hypoxia-inducible factor 1, were also able to
induce KSHV lytic replication. These studies suggest that hypoxia is an
inducer of KSHV replication. This process may play an important role in
the pathogenesis of KS.
(Blood. 2001;97:3244-3250) Kaposi sarcoma (KS) is a multifocal proliferative
disease of vascular origin. KS lesions are characterized by
proliferation and growth of spindle-shaped neoplastic cells that appear
to be of lymphatic endothelial cell origin.1-3 KS is the
most common neoplasm in human immunodeficiency virus type
1-infected individuals.1 Even before the advent
of acquired immunodeficiency syndrome (AIDS), KS was known to be more
prevalent in certain geographic areas and groups of patients (classic
and endemic KS). A classic form of KS is described as occurring in
elderly men in southern Italy and other Mediterranean
countries,4 and an endemic form of KS has been observed to
occur in sub-Saharan Africa.5,6 In addition, transplant
recipients and other immunosuppressed patients are at risk for
developing KS.4
Since the discovery of Kaposi sarcoma-associated herpesvirus (KSHV),
also called human herpesvirus-8 (HHV-8), in 1994,7 substantial evidence has been accumulated that implicates it as an
essential factor in the pathogenesis of all forms of
KS.8,9 It is also involved in the pathogenesis of primary
effusion lymphoma (PEL) and certain cases of multicentric Castleman
disease.10 KSHV DNA is detected in nearly all KS
lesions.7,11,12 As with other human herpesviruses,
infection with KSHV can be latent or lytic. Activation of viral
replication in latently infected B cells, endothelial cells, or other
target cells may be responsible for viral spread and contribute to the
development of KS.4 KSHV encodes for several cellular gene
mimics that are produced during lytic replication and that have
proangiogenic activity.13-16 The virus also encodes
several cellular protein mimics with oncogenic potential, such as
v-cyc, a D-type cyclin, and a member of the interferon
regulatory factor family.16 The production of these viral
factors during KSHV lytic replication may contribute to the development
of KS. Cells latently infected with KSHV can be activated to undergo
lytic replication by phorbol esters. However, relatively little is
presently known about the physiologic signals that serve to activate
KSHV in infected patients.
In his original description of KS in 1872, Moritz Kaposi noted that the
painful edema and characteristic lesions of the condition occurred
primarily on the feet of his patients, and we have been struck by a
predilection of KS to involve the feet in both classic and
AIDS-associated forms.17 The lower extremities often have relatively low tissue oxygen (O2)
concentrations,18 and we hypothesized that such hypoxic
conditions might reactivate KSHV and lead to the subsequent production
of proangiogenic factors, thus favoring the development of KS. In this
report, we investigated a possible role for hypoxia in the
re-activation of KSHV in 2 KSHV-infected PEL cell lines.
Cell culture at 21% and 1% O2
Analysis of KSHV lytic protein expression
by flow cytometry
Western blot analysis for the viral minor capsid protein The level of virus in the cellular supernatants of KSHV-infected cells was determined by means of a peptide affinity-purified rabbit polyclonal antibody directed toward a 17-amino acid peptide of the open reading frame 26 (ORF 26) minor capsid protein (mCP) of KSHV as described previously.22 To determine if we could use this assay to quantitatively measure the level of virus in the media, we measured the mCP band intensity for increasing concentrations of sucrose-purified KSHV (ABI, Columbia, MD) by Western blot. We found that the mCP band intensity, as determined by means of Un-Scan-It (Silk Scientific, Orem, UT), was directly proportional to the amount of virus loaded from 1 µg (equivalent to 3.3 × 107 viral particles) to 16 µg of viral lysate protein loaded. Cell culture samples were first centrifuged (10 minutes at 1000g) to remove the cells. The supernatant was ultracentrifuged in 1 to 1.5 mL aliquots at 100 000g for 35 minutes at 4°C. The pelleted material was washed with 1 mL cold PBS, pelleted as above, and then resuspended in sodium dodecyl sulfate sample buffer (Novex, San Diego, CA) and boiled at 70°C for 10 minutes. Samples that represented equal volumes of pelleted supernatant were electrophoresed on 10% or on 4% to 12% bis-Tris polyacrylamide gels with 2-(N-morphilino) ethanesulfonic acid running buffer, by means of the NuPage system (Novex). Proteins were electroblotted onto nitrocellulose, and the mCP was detected with a peptide affinity-purified rabbit antibody as previously described.22 Briefly, blots were incubated with anti-mCP rabbit antibody for 2 hours at room temperature and then for 30 minutes with an antirabbit secondary antibody conjugated to alkaline phosphatase. Bands were detected by means of the Western Blue-stabilized substrate for alkaline phosphatase (Promega, Madison, WI). The band was identified by comparison with a viral standard (ABI) containing the mCP band that migrated to an approximate molecular mass of 34 kd as determined by comparison with the migration positions of SeeBlue-prestained markers (Novex). Immunoblots were scanned, and densitometry analyses of the scanned images were performed.Enzyme-linked immunosorbent assays for viral interleukin 6 and vascular endothelial growth factor Levels of viral interleukin 6 (vIL-6) in culture supernatants were determined by means of a specific enzyme-linked immunosorbent assay as previously described.23 Briefly, polystyrene plates (Immunol 1B; Dynex Technologies, Chantilly, VA) were coated with mouse monoclonal antivIL-6 antibody (v6m12.1.1, 4 µg/mL in carbonate buffer, pH 9) overnight at 4°C. After washing the plates with PBS containing 0.05% Tween 20 (PBS-T) and blocking with SuperBlock (Pierce, Rockford, IL), test samples were added in duplicate to the wells. These samples were diluted in advance with the same volume of PBS-T containing 10% fetal bovine serum (FBS); final concentration of FBS was 10% for both samples and standards. Plates were incubated overnight at room temperature and washed with PBS-T. Maltose-binding protein (MBP)-absorbed rabbit polyclonal anti-vIL-6 antibody (0.5 µg/mL) was added to the wells in PBS-T containing 0.5% bovine serum albumin (BSA) (PBS-T/BSA). Plates were incubated for 2 hours at room temperature and washed. Affinity-purified human serum protein-absorbed goat antirabbit immunoglobulin G antibody conjugated to alkaline phosphatase (Sigma) (1:400 dilution in PBS-T/BSA) was added. Plates were incubated at room temperature for 1.5 hours and washed with PBS-T. A p-nitrophenolphosphate substrate (Sigma) was added to the wells, and the plates were read at 405 nm with correction at
595 nm. A purified fusion protein of MBP (42.7 kd) and amino acids 22 through 204 of vIL-6 (21.6 kd) were used as standards. The
concentration of vIL-6 was calculated from absorbance values in
relation to the standard curve, corrected for the presence of the MBP
fusion protein in the vIL-6 standard (vIL-6 corresponds to 33.6% of
MBP vIL-6). The assay sensitivity is approximately 30 pg/mL for vIL-6.
Vascular endothelial growth factor (VEGF) was determined in the
supernatant of cells by means of the Human VEGF kit from Accucyte
(College Park, MD) with a dynamic range of 0.195 to 50 ng/mL VEGF.
Statistical analysis The exact Wilcoxon rank sum test was used to compare expression of KSHV-encoded antigens in cells cultured under normoxia and cells cultured under chronic hypoxia. The Wilcoxon signed rank test was used to compare parallel cultures established under normoxia and acute hypoxia at the same time.
Hypoxia increases KSHV lytic protein expression in KSHV-infected PEL B-cell lines BC-3 and BCBL-1 PEL B-cell lines were used to study the role of hypoxia in KSHV reactivation. Viral reactivation was determined, in part, by studying the expression of 2 lytic proteins, PF-8 and gpK8.1, by flow cytometry. In normoxia (21% O2), the percentage of viable cells expressing the early-lytic protein PF-8 was very low: 0.12% and 0.23% for BC-3 and BCBL-1 cells, respectively. Also, the median percentage of cells expressing the late-lytic protein gpK8.1 was very low, 0.04% and 0.09% for BC-3 and BCBL-1 cells, respectively (Figure 1). However, when BC-3 cells were maintained under chronic hypoxic conditions (1% O2 for more than 3 cell passages), the median percentage of viable BC-3 cells expressing PF-8 increased to 2.7%, a 22-fold increase (P = .012) (Figure 1A). A similar increase in PF-8 expression from 0.23% to 2.86% was seen in BCBL-1 cells, representing a 12-fold increase (P = .004) (Figure 1B). Late-lytic gpK8.1 protein expression was also greater under hypoxic conditions, with BC-3 cells having a median increase from 0.04% to 0.55% (13-fold increase) (P = .016) and BCBL-1 cells having a median increase from 0.09% to 0.94% (10-fold increase) (P = .028) (Figure 1A,B). It was observed throughout these experiments that the cells grown in chronic hypoxia had a somewhat lower cell growth rate and viability. This decrease in viability seen in chronic hypoxia ranged from 10% to 25% compared with cells grown in normoxia.
The effect of acute hypoxia on KSHV lytic replication was also investigated. An increase in the expression of both lytic proteins, similar to that observed in chronic hypoxia, occurred in the B-cell lines when acutely exposed to hypoxia (Figure 1C,D). However, the extent of the increase in PF-8 expression as a result of acute hypoxic exposure varied somewhat from experiment to experiment, ranging from a 7.7- to a 34-fold induction in BC-3 (median increase, 9.7-fold) (Figure 1C,D). Similarly, there was a 3- to 12-fold induction of gpK8.1 (median increase, 6-fold) in BC-3 cells (not shown). Acute hypoxia also increased PF-8 expression in BCBL-1 cells, but to a lesser degree than that seen for BC-3 cells (Figure 1C,D). Hypoxia enhances TPA induction of KSHV lytic replication TPA is an inducer of KSHV lytic replication in PEL cell lines infected with KSHV.19,24 It was previously shown that the maximum percentages of cells that could be induced to undergo lytic replication (based on PF-8 expression quantitated by flow cytometry) by 30 nM TPA 3 days after treatment in BCBL-1 and BC-3 cells were approximately 12% and 20%, respectively.21 We were interested in determining whether hypoxia would affect lytic induction by TPA in the 2 cell lines used. When cells exposed to chronic hypoxia were treated with 30 nM TPA, substantial toxicity (less than 40% viability) occurred in both of the cell lines. A viability of less than 40% was our cutoff for assaying the level of lytic protein expression, and protein expression was therefore not determined for this concentration of TPA. Therefore, the effect of chronic hypoxia on viral reactivation by TPA was assessed at lower TPA concentrations. When cells were grown in normoxia and treated with a suboptimal concentration of TPA (6.4 nM), the median percentage of cells expressing PF-8 was 8.6% for BC-3 and 3.9% for BCBL-1 cells as determined by flow cytometry (Figure 1C,D). However, the median level of PF-8 expression more than doubled when these TPA-treated cells were exposed to acute hypoxia, resulting in 10.3% expression for BCBL-1 cells and 20.0% expression for BC-3 cells (Figure 1C,D).We then assessed the effect of both acute and chronic hypoxia on
the lytic protein expression induced by various doses of TPA. As
expected, TPA increased PF-8 and gpK8.1 expression in a dose-dependent
manner 2 days after treatment in normoxic conditions (Figure
2). However, the level of lytic protein
expression in response to TPA was significantly increased in cells
exposed to both acute and chronic hypoxia (Figure 2). Acute hypoxia was
more effective than chronic hypoxia at enhancing the induction of PF-8 and gpK8.1 expression in the presence of TPA for both PEL cell lines.
Detection of KSHV mCP under normoxic and hypoxic conditions To determine whether exposure to 1% O2 (hypoxia) also affected virus production from KSHV-infected cells, we assayed for mCP in culture supernatants under these conditions. Under normoxic conditions, we could not detect mCP in pellets from 1 to 1.5 mL supernatants from BCBL-1 or BC-3 cells. However, mCP was detected in supernatants from BCBL-1 and BC-3 cells exposed to chronic hypoxia (Figure 3A). BCBL-1 cells cultured in 5% O2 also produced increased levels of mCP, although to a lesser degree than that seen at 1% O2 (data not shown). In addition, BCBL-1 and BC-3 cells exposed to a suboptimal concentration of TPA produced higher levels of mCP when exposed to acute hypoxia (Figure 3B). A low level of the mCP was detected 2 days after 6.4-nM TPA treatment in the supernatant of cells grown in 21% O2, and the level further increased over the next 2 days, reaching a maximum on day 4 (Figure 3B). When cells were exposed to acute hypoxia and 6.4 nM TPA, there was a 5-fold increase in the level of mCP observed 2 days after transfer to hypoxic conditions, as compared with TPA-treated cells in normoxia. In addition, when cells were exposed to hypoxia, the level of mCP reached a maximum a day earlier than for cells in normoxia (Figure 3B). Qualitatively similar results were obtained with BC-3 cells (data not shown). We also performed a TPA dose-response experiment to determine the effect of chronic hypoxia on TPA induction of virus. Again, the cells grown in chronic hypoxia produced detectable mCP even in the absence of TPA induction; those grown in normoxia did not. TPA treatment at all concentrations further increased mCP production in cells exposed to hypoxia; cells exposed to normoxia produced measurable virus only at the 2 highest TPA concentrations (6.4 and 30 nM) (results not shown).
Hypoxia is known to induce the production of VEGF in normal cells, and we considered whether VEGF production induced by hypoxia in the PEL cells might have acted in an autocrine manner to reactive KSHV replication. Consistent with a previous report,25 BC-3 cells produced substantial VEGF (1.43 ng/106 cells; 2.8 ng/mL media) after 3 days of culture under normoxic conditions. However, although there was a small increase in the VEGF produced per cell when these cells were exposed to 1% O2 (to 2.5 ng/106 cells), there was no net change in the VEGF released into the media (2.75 ng/mL media). Also, addition of VEGF at 10 or 100 ng/mL for 3 days had no substantial effect on the level of expression of PF-8 or gpK8.1 by BC-3 or BCBL-1 cells over that seen in control cells. Taken together, these results suggest that hypoxia-induced KSHV reactivation was not the result of an up-regulation of VEGF in these cells by hypoxia. Effect of hypoxia on the induction of KSHV vIL-6 production Viral IL-6 is a cytokine thought to play a role in the pathogenesis of KS by stimulating spindle cell growth and activating the production of angiogenic factors from these cells.15,26 Acute exposure of BCBL-1 cells to hypoxia alone was found to induce vIL-6 production approaching the levels induced with 6.4 nM TPA (Figure 4A). When cells were exposed to hypoxia and treated with 6.4 nM TPA, there was a further increase in vIL-6 production over that caused by each treatment alone (Figure 4A). The level of vIL-6 increased in parallel with the extent of lytic intracellular protein expression as determined by flow cytometry (Figure 4B). In 3 different experiments with BC-3 cells, the level of vIL-6 increased in response to acute hypoxia from an average of 245 pg/mL in normoxia to 611 pg/mL in hypoxia.
Effect of hypoxia-inducible-factor-inducing agents Dfx and CoCl2 on KSHV protein expression One of the primary mediators of the response of cells to low O2 is hypoxia-inducible factor 1 alpha (HIF-1 ). Under
normal conditions, HIF-1 is rapidly degraded, but this process is
inhibited under hypoxic conditions.27 To investigate the
ability of increased HIF-1 to reactivate KSHV replication, we tested
the effects of 2 commonly used inducers of HIF-1, Dfx and
CoCl2, on KSHV-infected cells.28 In a
dose-dependent manner, CoCl2 treatment in normoxic conditions increased the percentage of BCBL-1 cells expressing PF-8 and
gpK8.1 (Figure 5); at 200 µM
CoCL2, the level of antigen expression was close to that
obtained with cells exposed to 30 nM TPA21 (compare Figure
2). CoCl2 also enhanced the lytic protein expression
induced by 6.4 nM TPA up to 2-fold and increased vIL-6 levels in
culture supernatants (data not shown). Although less effective than
CoCl2, treatment of BCBL-1 cells with Dfx increased PF-8
protein expression from an average of 0.43% for untreated cells to
0.88% and 1.2% for concentrations of 5 µM and 10 µM, respectively. Concentrations above 200 µM CoCl2 and 20 µM Dfx led
to substantial toxicity (less than 40% viability), and therefore samples were not measured for lytic protein expression.
Although KSHV can be activated by phorbol esters in the laboratory, the physiologic stimuli involved in the reactivation of KSHV from its latent state in B cells, endothelial cells, and other target cells in the body are poorly understood. Our studies indicate that hypoxia (1% O2) can activate lytic replication of KSHV in 2 different PEL B-cell lines and increase the expression of the proangiogenic factor vIL-6. Some activation was observed with a higher O2 saturation (5% O2). An O2 saturation as low as 2.5% can be found in certain tissues under physiological conditions,29 and a saturation of 1% or lower can be found under certain pathologic conditions,30,31 including vascular ischemia of the legs.32 This suggests that hypoxia-induced KSHV activation may be important in the life cycle of this virus and contribute to KS pathogenesis. In addition, we found that hypoxia potentiates TPA-induced KSHV activation, suggesting that this stimulus may work in concert with other inducers of KSHV replication. We have not determined if endothelial cells infected with HHV-8 would respond similarly to hypoxia, and therefore future studies on these cells will be required to determine the extent of involvement of hypoxia in HHV-8 pathogenesis. Although the percentage of cells induced to undergo lytic replication by hypoxia is less than the maximal level induced by phorbol esters, it represents a median increase of up to 22-fold over the background replication obtained under normoxic conditions. It is worth noting that our data, as well as previous studies,21 suggest that there may be a limit to the percentage of cells that can be activated into the lytic phase. It was previously reported that a maximum of approximately 15% live BCBL-1 cells can be induced into the lytic phase and that for BC-3 cells the maximum is closer to 20% to 25%. The reason a substantially higher percentage of live cells do not undergo lytic replication with hypoxia alone is unclear, but could be related to a cell-cycle-related restriction of KSHV reactivation. Also, although hypoxia enhanced TPA-induced replication, we found that combining a high level of TPA (eg, 30 nM) and hypoxia led to significant cellular toxicity. To what extent this represents direct cellular toxicity as a result of the combined effects of hypoxia and TPA, as opposed to cell death from increased KSHV lytic replication under these conditions, is not clear at this time. Hypoxia induces a number of effects through an increase in the
intracellular levels of HIF-1 KSHV encodes a number of proangiogenic human factors, including vIL-6, viral macrophage inflammatory protein 1 (vMIP-I), and vMIP-II, that are thought to be involved in the pathogenesis of KS. In addition, ORF 74 of KSHV encodes a constitutively active G-protein-coupled receptor that stimulates the production of cellular proangiogenic factors, and by these means, the virus could induce the proliferation of vascular endothelial cells.38,39 These viral-encoded proteins are all produced or increased during lytic KSHV replication.24 Thus, hypoxic conditions such as may occur at the edges of a wound may induce both lytic KSHV replication and the growth of target endothelial cells. This may provide a mechanism to aid the establishment of infection if this virus enters the body through a cut in the skin or mucosal tissue. Hypoxic conditions may activate the virus and contribute to the development of KS after localized infection of cells by KSHV. There is some evidence to indicate that hypoxia may affect the replication of certain other viruses as well.40 In particular, it has been reported that replication of herpes simplex virus type 2 can be increased 3- to 5-fold by exposure of infected cells to low O2 concentrations.40 Also, there is some evidence that production of Coxsackie virus can be either decreased or increased by exposure to hypoxia and that expression of HBx protein by hepatitis B-infected hepatoma cells is enhanced by hypoxia.41 What is noteworthy about KSHV, however, is the combination of viral induction by hypoxia and hypoxia-induced production of proangiogenic factors that could promote the growth of endothelial target cells. The findings in this study may also explain certain clinical and epidemiological features of KS. Although there are reports that advanced KS may involve a monoclonal proliferation,42 the best available evidence suggests that spindle cell proliferation induced directly and/or indirectly by KSHV-encoded genes plays an important role in the development and progression of this condition.43-45 Hypoxia-induced KSHV reactivation may contribute to the increased prevalence of KS in patients with diabetes mellitus,46,47 as this condition is often associated with vascular disease and poor circulation. It may also contribute to the tendency of KS to occur on the lower legs, especially in the elderly men who develop classic KS. Hypoxic tissues may also produce VEGF as a direct result of hypoxia, and this may work in tandem with hypoxia-induced KSHV replication to promote spindle cell growth. Additional studies will be needed to further understand how these factors may interact in the pathogenesis of KS. Activation of lytic KSHV infection by hypoxia may also help explain the pattern of distribution of KSHV infection and KS in the world. Unlike other human herpesviruses, which infect almost all individuals worldwide, the prevalence of KSHV infection varies widely from region to region.9,48,49 Interestingly, the prevalence of KSHV infection and KS is especially high in areas of the world where malaria is still endemic (eg, sub-Saharan Africa) or where a subset of the population has hereditary anemias, such as thalassemia, that confer partial protection against malaria (eg, southern Italy and other Mediterranean areas).4,50,51 It is possible that tissue hypoxia in patients with malaria or hereditary animas leads to increased shedding of KSHV and spread of the virus to other individuals. In summary, our study provides evidence that KSHV can be activated by exposure of latently infected B-cell lines to hypoxia and that hypoxia can potentiate activation of KSHV by TPA. This finding may be important in the epidemiology and life cycle of KSHV and in the pathogenesis of KS. Further study of this phenomenon may lead to strategies to prevent or treat KSHV-related diseases.
We thank Isaac Rodriguez-Chavez for critical reading of the manuscript and Seth M. Steinberg and Jodi Black for assistance and advice.
Submitted October 6, 2000; accepted January 23, 2001.
D.A.D and A.S.R. contributed equally to this manuscript.
This is a US goverment work. There are no restrictions on its use.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: David A. Davis, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 10S255, MSC 1868, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: dadavis{at}helix.nih.gov.
1. Longo DL, Steis RG, Lane HC, et al. Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results. Ann N Y Acad Sci. 1984;437:421-430[CrossRef][Medline] [Order article via Infotrieve].
2.
Dupin N, Fisher C, Kellam P, et al.
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
Proc Natl Acad Sci U S A.
1999;96:4546-4551
3.
Antman K, Chang Y.
Kaposi's sarcoma.
N Engl J Med.
2000;342:1027-1038 4. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000;88:500-517[CrossRef][Medline] [Order article via Infotrieve]. 5. Stein ME, Spencer D, Ruff P, Lakier R, MacPhail P, Bezwoda WR. Endemic African Kaposi's sarcoma: clinical and therapeutic implications: 10-year experience in the Johannesburg Hospital (1980-1990). Oncology. 1994;51:63-69[Medline] [Order article via Infotrieve]. 6. Friedman-Kien AE, Saltzman BR. Clinical manifestations of classical, endemic African, and epidemic AIDS-associated Kaposi's sarcoma. J Am Acad Dermatol. 1990;22:1237-1250[Medline] [Order article via Infotrieve].
7.
Chang Y, Cesarman E, Pessin MS, et al.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science.
1994;266:1865-1869 8. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995;346:799-802[CrossRef][Medline] [Order article via Infotrieve]. 9. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996;2:925-928[CrossRef][Medline] [Order article via Infotrieve].
10.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N Engl J Med.
1995;332:1186-1191
11.
Moore PS, Chang Y.
Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection.
N Engl J Med.
1995;332:1181-1185 12. Chuck S, Grant RM, Katongole-Mbidde E, Conant M, Ganem D. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996;173:248-251[Medline] [Order article via Infotrieve].
13.
Boshoff C, Endo Y, Collins PD, et al.
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.
Science.
1997;278:290-294 14. Nicholas J, Ruvolo VR, Burns WH, et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3:287-292[CrossRef][Medline] [Order article via Infotrieve]. 15. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839-842[Abstract].
16.
Moore PS, Boshoff C, Weiss RA, Chang Y.
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV.
Science.
1996;274:1739-1744
17.
Kaposi M.
Idiopathic multiple pigmented sarcoma of the skin.
CA Cancer J Clin.
1982;32:342-347 18. Ubbink DT, Tulevski II, den Hartog D, Koelemay MJ, Legemate DA, Jacobs MJ. The value of non-invasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 1997;13:296-300[CrossRef][Medline] [Order article via Infotrieve]. 19. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2:342-346[CrossRef][Medline] [Order article via Infotrieve].
20.
Arvanitakis L, Mesri EA, Nador RG, et al.
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood.
1996;88:2648-2654
21.
Zoeteweij JP, Eyes ST, Orenstein JM, et al.
Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents.
J Virol.
1999;73:5894-5902 22. Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis. 1997;175:1071-1079[Medline] [Order article via Infotrieve].
23.
Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G.
Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions.
Blood.
2000;96:1599-1601
24.
Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS.
Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1).
J Virol.
1998;72:1005-1012
25.
Aoki Y, Tosato G.
Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas.
Blood.
1999;94:4247-4254
26.
Molden J, Chang Y, You Y, Moore PS, Goldsmith MA.
A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit.
J Biol Chem.
1997;272:19625-19631 27. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-578[CrossRef][Medline] [Order article via Infotrieve].
28.
Wang GL, Semenza GL.
Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.
Blood.
1993;82:3610-3615
29.
Jiang BH, Semenza GL, Bauer C, Marti HH.
Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension.
Am J Physiol.
1996;271:C1172-1180 30. Chang N, Goodson WH, Gottrup F, Hunt TK. Direct measurement of wound and tissue oxygen tension in postoperative patients. Ann Surg. 1983;197:470-478[Medline] [Order article via Infotrieve].
31.
Semenza GL.
HIF-1: mediator of physiological and pathophysiological responses to hypoxia.
J Appl Physiol.
2000;88:1474-1480 32. Lantsberg L, Goldman M. Laser Doppler flowmetry, transcutaneous oxygen tension measurements and Doppler pressure compared in patients undergoing amputation. Eur J Vasc Surg. 1991;5:195-197[CrossRef][Medline] [Order article via Infotrieve]. 33. Richard DE, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun. 1999;266:718-722[CrossRef][Medline] [Order article via Infotrieve]. 34. Semenza GL. Perspectives on oxygen sensing. Cell. 1999;98:281-284[CrossRef][Medline] [Order article via Infotrieve].
35.
Semenza GL, Roth PH, Fang HM, Wang GL.
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
J Biol Chem.
1994;269:23757-23763
36.
Liu Y, Cox SR, Morita T, Kourembanas S.
Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5' enhancer.
Circ Res.
1995;77:638-643
37.
Lukac DM, Kirshner JR, Ganem D.
Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.
J Virol.
1999;73:9348-93461
38.
Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS.
Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma.
Proc Natl Acad Sci U S A.
1997;94:979-984 39. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86-89[CrossRef][Medline] [Order article via Infotrieve]. 40. Ebbesen P, Toth FD, Villadsen JA, Norskov-Lauritsen N. In vitro interferon and virus production at in vivo physiologic oxygen tensions. In Vivo. 1991;5:355-358[Medline] [Order article via Infotrieve]. 41. Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun. 2000;268:456-461[CrossRef][Medline] [Order article via Infotrieve].
42.
Rabkin CS, Janz S, Lash A, et al.
Monoclonal origin of multicentric Kaposi's sarcoma lesions.
N Engl J Med.
1997;336:988-993 43. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev. 1992;127:147-155[CrossRef][Medline] [Order article via Infotrieve]. 44. Yarchoan R. Therapy for Kaposi's sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S66-S73.
45.
Miles SA, Rezai AR, Salazar-Gonzalez JF, et al.
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
Proc Natl Acad Sci U S A.
1990;87:4068-4072 46. Laor Y, Schwartz RA. Epidemiologic aspects of American Kaposi's sarcoma. J Surg Oncol. 1979;12:299-303[Medline] [Order article via Infotrieve]. 47. Friedman-Birnbaum R, Weltfriend S, Katz I. Kaposi's sarcoma: retrospective study of 67 cases with the classical form. Dermatologica. 1990;180:13-17[Medline] [Order article via Infotrieve]. 48. Cook PM, Whitby D, Calabro ML, et al. Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. International Collaborative Group. AIDS. 1999;13:1165-1176[CrossRef][Medline] [Order article via Infotrieve]. 49. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996;348:1133-1138[CrossRef][Medline] [Order article via Infotrieve]. 50. Sarid R, Olsen SJ, Moore PS. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res. 1999;52:139-232[Medline] [Order article via Infotrieve]. 51. Franceschi S, Geddes M. Epidemiology of classic Kaposi's sarcoma, with special reference to Mediterranean population. Tumori. 1995;81:308-314[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. Dalton-Griffin, S. J. Wilson, and P. Kellam X-Box Binding Protein 1 Contributes to Induction of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle under Hypoxic Conditions J. Virol., July 15, 2009; 83(14): 7202 - 7209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Anderson, C. Lauria, N. Romano, E. E. Brown, D. Whitby, B. I. Graubard, Y. Li, A. Messina, L. Gafa, F. Vitale, et al. Risk Factors for Classical Kaposi Sarcoma in a Population-based Case-control Study in Sicily Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3435 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Shin, C.-H. Joo, M. U. Gack, H.-R. Lee, and J. U. Jung Kaposi's Sarcoma-Associated Herpesvirus Viral IFN Regulatory Factor 3 Stabilizes Hypoxia-Inducible Factor-1{alpha} to Induce Vascular Endothelial Growth Factor Expression Cancer Res., March 15, 2008; 68(6): 1751 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Majerciak, K. Yamanegi, E. Allemand, M. Kruhlak, A. R. Krainer, and Z.-M. Zheng Kaposi's Sarcoma-Associated Herpesvirus ORF57 Functions as a Viral Splicing Factor and Promotes Expression of Intron-Containing Viral Lytic Genes in Spliceosome-Mediated RNA Splicing J. Virol., March 15, 2008; 82(6): 2792 - 2801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Cai, M. Murakami, H. Si, and E. S. Robertson A Potential {alpha}-Helix Motif in the Amino Terminus of LANA Encoded by Kaposi's Sarcoma-Associated Herpesvirus Is Critical for Nuclear Accumulation of HIF-1{alpha} in Normoxia J. Virol., October 1, 2007; 81(19): 10413 - 10423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Davis, K. E. Singer, I. P. Reynolds, M. Haque, and R. Yarchoan Hypoxia Enhances the Phosphorylation and Cytotoxicity of Ganciclovir and Zidovudine in Kaposi's Sarcoma-Associated Herpesvirus Infected Cells Cancer Res., July 15, 2007; 67(14): 7003 - 7010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Morris, R. R. Arnold, and J. Webster-Cyriaque Signaling Cascades Triggered by Bacterial Metabolic End Products during Reactivation of Kaposi's Sarcoma-Associated Herpesvirus J. Virol., June 1, 2007; 81(11): 6032 - 6042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izumiya, C. Izumiya, A. Van Geelen, D.-H. Wang, K. S. Lam, P. A. Luciw, and H.-J. Kung Kaposi's Sarcoma-Associated Herpesvirus-Encoded Protein Kinase and Its Interaction with K-bZIP J. Virol., February 1, 2007; 81(3): 1072 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Puppo, M. C. Bosco, M. Federico, S. Pastorino, and L. Varesio Hypoxia inhibits Moloney murine leukemia virus expression in activated macrophages J. Leukoc. Biol., February 1, 2007; 81(2): 528 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Carroll, H. L. Kenerson, R. S. Yeung, and M. Lagunoff Latent Kaposi's Sarcoma-Associated Herpesvirus Infection of Endothelial Cells Activates Hypoxia-Induced Factors J. Virol., November 1, 2006; 80(21): 10802 - 10812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Cai, K. Lan, S. C. Verma, H. Si, D. Lin, and E. S. Robertson Kaposi's Sarcoma-Associated Herpesvirus Latent Protein LANA Interacts with HIF-1{alpha} To Upregulate RTA Expression during Hypoxia: Latency Control under Low Oxygen Conditions. J. Virol., August 1, 2006; 80(16): 7965 - 7975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haque, V. Wang, D. A. Davis, Z.-M. Zheng, and R. Yarchoan Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster J. Virol., July 15, 2006; 80(14): 7037 - 7051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lu, L. Day, S.-J. Gao, and P. M. Lieberman Acetylation of the Latency-Associated Nuclear Antigen Regulates Repression of Kaposi's Sarcoma-Associated Herpesvirus Lytic Transcription. J. Virol., June 1, 2006; 80(11): 5273 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Servais, P. Caillet-Fauquet, M.-L. Draps, T. Velu, Y. de Launoit, and A. Brandenburger Hypoxic-response elements in the oncolytic parvovirus Minute virus of mice do not allow for increased vector production at low oxygen concentration. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1197 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cohen, C. Brodie, and R. Sarid An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J. Gen. Virol., April 1, 2006; 87(Pt 4): 795 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen and M. Lagunoff Establishment and Maintenance of Kaposi's Sarcoma-Associated Herpesvirus Latency in B Cells J. Virol., November 15, 2005; 79(22): 14383 - 14391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lu, L. Day, and P. M. Lieberman Kaposi's Sarcoma-Associated Herpesvirus Virion-Induced Transcription Activation of the ORF50 Immediate-Early Promoter J. Virol., October 15, 2005; 79(20): 13180 - 13185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E Brown, D. Whitby, F. Vitale, P. C. Fei, C. Del Carpio, V. Marshall, A. J Alberg, D. Serraino, A. Messina, L. Gafa, et al. Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma Int. J. Epidemiol., October 1, 2005; 34(5): 1110 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lan, D. A. Kuppers, S. C. Verma, N. Sharma, M. Murakami, and E. S. Robertson Induction of Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen by the Lytic Transactivator RTA: a Novel Mechanism for Establishment of Latency J. Virol., June 15, 2005; 79(12): 7453 - 7465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Wang, D. A. Davis, M. Haque, L. E. Huang, and R. Yarchoan Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1{alpha} and Hypoxia-Inducible Factor-2{alpha} in HEK293T Cells Cancer Res., April 15, 2005; 65(8): 3299 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lan, D. A. Kuppers, and E. S. Robertson Kaposi's Sarcoma-Associated Herpesvirus Reactivation Is Regulated by Interaction of Latency-Associated Nuclear Antigen with Recombination Signal Sequence-Binding Protein J{kappa}, the Major Downstream Effector of the Notch Signaling Pathway J. Virol., March 15, 2005; 79(6): 3468 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. McAllister, S. G. Hansen, I. Messaoudi, J. Nikolich-Zugich, and A. V. Moses Increased Efficiency of Phorbol Ester-Induced Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus during S Phase J. Virol., February 15, 2005; 79(4): 2626 - 2630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Deutsch, A. Cohen, G. Kazimirsky, S. Dovrat, H. Rubinfeld, C. Brodie, and R. Sarid Role of Protein Kinase C {delta} in Reactivation of Kaposi's Sarcoma-Associated Herpesvirus J. Virol., September 15, 2004; 78(18): 10187 - 10192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Glaunsinger and D. Ganem Highly Selective Escape from KSHV-mediated Host mRNA Shutoff and Its Implications for Viral Pathogenesis J. Exp. Med., August 2, 2004; 200(3): 391 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haque, D. A. Davis, V. Wang, I. Widmer, and R. Yarchoan Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Contains Hypoxia Response Elements: Relevance to Lytic Induction by Hypoxia J. Virol., June 15, 2003; 77(12): 6761 - 6768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Dourmishev, A. L. Dourmishev, D. Palmeri, R. A. Schwartz, and D. M. Lukac Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis Microbiol. Mol. Biol. Rev., June 1, 2003; 67(2): 175 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yarchoan, D. A. Davis, A. Rinderknecht, and J. Webster-Cyriaque Development of Kaposi's Sarcoma at the Site of a Biopsy N. Engl. J. Med., September 5, 2002; 347(10): 763 - 764. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
20°C until use.
) and gpK8.1 (
)
expression represent the median of at least 3 independent
experiments ± the 25% and 75% quartiles. Exact Wilcoxon rank
sum test (unpaired) for panel A: (BC-3, PF-8 21% O2 vs 1%
O2) p2 =0 .0012, and (BC-3, gpK8.1 21%
O2 vs 1% O2) p2 = 0.016. Exact
Wilcoxon rank sum test (unpaired) for panel B: (BCBl-1, PF-8 21%
O2 vs 1% O2) p2 = 0.004, and
(BCBL-1, gpK8.1 21% O2 vs 1% O2)
p2 = 0.028. (C, D) Cells grown in normoxia were incubated
in 21% O2 or 1% O2 overnight. They were then
exposed to TPA (6.4 nM) or to media control and returned to their
respective conditions. The plotted values for PF-8 expression is the
median percentage of positive cells for 6 independent experiments ± the 25% and 75% quartiles. Wilcoxon signed rank test (paired) for
panel C: (BC-3, PF-8 21% O2 vs 1% O2)
p2 = 0.031, and (BC-3/TPA, PF-8 21% O2 vs 1%
O2) p2 = 0.031. Wilcoxon signed rank test
(paired) for panel D: (BCBL-1, PF-8 21% O2 vs 1%
O2) p2 = 0.031, and (BCBL-1/TPA, PF-8 21%
O2 vs 1% O2) p2 = 0.031.
) or acute hypoxia (
).
(B) gpK8.1 expression in BCBL-1 cells in normoxia (
